Targets › ITGB8
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Integrin alpha-V:beta-8 (ITGAV:ITGB8) is a receptor for fibronectin. It recognizes the sequence R-G-D in its ligands. (UniProt, P26012)
Open in Phaseline: the race on ITGB8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals | CRB-601 αvβ8 integrin antagonist monoclonal antibody | ITGAV, ITGB8 | Phase 1 | Solid Tumor | Dec 2026 |
Solid Tumor (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.